lancet-header

Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com.

Incidence and Mortality of Multiple Myeloma in China, 2006-2016: An Analysis of the Global Burden of Disease Study 2016

22 Pages Posted: 8 Jul 2019

See all articles by Jiangmei Liu

Jiangmei Liu

Collaborative Innovation Center for Diagnosis Treatment of Infectious Diseases - National Center for Chronic and Noncommunicable Disease Control and Prevention

Weiping Liu

Peking University - Key Laboratory of Carcinogenesis and Translational Research

Xinying Zeng

Collaborative Innovation Center for Diagnosis Treatment of Infectious Diseases - National Center for Chronic and Noncommunicable Disease Control and Prevention

Jun Ma

Harbin Institute of Hematology & Oncology

Lijun Wang

Collaborative Innovation Center for Diagnosis Treatment of Infectious Diseases - National Center for Chronic and Noncommunicable Disease Control and Prevention

Union for China Lymphoma Investigators of the Chinese Society of Clinical Oncology

Union for China Leukemia Investigators of the Chinese Society of Clinical Oncology

More...

Abstract

Background: The accurate information about burden of multiple myeloma (MM) at national and provincial level remain unknown in China.

Methods: We used data from the Global Burden of Disease Study 2016 (GBD 2016) to calculate the burden of MM and to describe the temporal trend in China.

Findings: It was estimated that there were 16 500 new cases and 10 300 deaths of multiple myeloma in China. The age-standardized incidence rates (ASIR) and mortality rates (ASMR) per 100 000 population were 1.03 (95%UI, 0.88-1.17) and 0.67 (95%UI, 0.59-0.77). Males had higher incidence and mortality rates than females in all age groups. An upward trend with age in incidence and mortality were observed. Furthermore, higher incidence and mortality rates clustered in those developed provinces. The incidence of MM in China increased significantly from 2006 to 2016, while the mortality increased from 2006 to 2014, and then remained stable from 2014 to 2016.

Interpretation: The burden of MM had a heterogeneous pattern in China, which highlighted the need of differentiated disease prevention and control strategies in both national and provincial levels.

Funding Statement: China Special Program for Basic Research 2014 from Ministry of Science and Technology (Grant number: 2014FY121100).

Declaration of Interests: The authors declare no competing interests.

Ethics Approval Statement: Not required.

Keywords: Multiple Myeloma; Incidence; Mortality; Epidemiology

Suggested Citation

Liu, Jiangmei and Liu, Weiping and Zeng, Xinying and Ma, Jun and Wang, Lijun and Oncology, Union for China Lymphoma Investigators of the Chinese Society of Clinical and Oncology, Union for China Leukemia Investigators of the Chinese Society of Clinical, Incidence and Mortality of Multiple Myeloma in China, 2006-2016: An Analysis of the Global Burden of Disease Study 2016 (July 3, 2019). Available at SSRN: https://ssrn.com/abstract=3414437 or http://dx.doi.org/10.2139/ssrn.3414437

Jiangmei Liu

Collaborative Innovation Center for Diagnosis Treatment of Infectious Diseases - National Center for Chronic and Noncommunicable Disease Control and Prevention ( email )

Beijing 100050
China

Weiping Liu

Peking University - Key Laboratory of Carcinogenesis and Translational Research ( email )

No. 38 Xueyuan Road
Haidian District
Beijing, Beijing 100871
China

Xinying Zeng

Collaborative Innovation Center for Diagnosis Treatment of Infectious Diseases - National Center for Chronic and Noncommunicable Disease Control and Prevention ( email )

Beijing 100050
China

Jun Ma (Contact Author)

Harbin Institute of Hematology & Oncology ( email )

Harbin
China
86 0451 84694406 (Phone)

Lijun Wang

Collaborative Innovation Center for Diagnosis Treatment of Infectious Diseases - National Center for Chronic and Noncommunicable Disease Control and Prevention ( email )

Beijing 100050
China

Click here to go to TheLancet.com

Paper statistics

Abstract Views
316
Downloads
22
PlumX Metrics